Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 3Phase 3 2

Status

Completed 19Unknown 2Terminated 2Recruiting 2Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Breast Neoplasms 108Carcinoma, Non-Small-Cell Lung 95Prostatic Neoplasms 58Multiple Myeloma 45Neoplasms 38Neoplasm Metastasis 33Ovarian Neoplasms 26Melanoma 24Urinary Bladder Neoplasms 23Lung Neoplasms 22Colorectal Neoplasms 22Recurrence 21Leukemia, Lymphocytic, Chronic, B-Cell 21Parkinson Disease 4, Autosomal Dominant Lewy Body 20Carcinoma, Renal Cell 20Carcinoma, Hepatocellular 17Triple Negative Breast Neoplasms 16Nasopharyngeal Carcinoma 16Lymphoma, Non-Hodgkin 16Stomach Neoplasms 15Leukemia, Myeloid, Acute 15Lymphoma 14Squamous Cell Carcinoma of Head and Neck 13Small Cell Lung Carcinoma 13Fallopian Tube Neoplasms 12Colonic Neoplasms 12Carcinoma 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Lymphoma, Large B-Cell, Diffuse 11Lymphoma, Follicular 11

Interventions

Dexamethasone 2Cyclophosphamide 2Clinical Protocols 2Bortezomib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Active not recruiting × Immunoglobulin Light-chain Amyloidosis × Clear all
NCT04512235 2026-04-07

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

Alexion Pharmaceuticals, Inc.

Phase 3 Active not recruiting
281 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT04504825 2026-03-17

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

Alexion Pharmaceuticals, Inc.

Phase 3 Active not recruiting
125 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡